<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thrombolytic therapies have perhaps been the most important single development in the management of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Results of the National Institute of <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">Neurologic disorders</z:e> and <z:hpo ids='HP_0001297'>Stroke</z:hpo> (NINDS) trial revealed a 30% greater chance of being disability free at three months if patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> were treated with recombinant tissue plasminogen activator (rt-PA) within 3 hours of <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>These results have been validated in large community studies in the United States </plain></SENT>
<SENT sid="3" pm="."><plain>The Prolyse in <z:hpo ids='HP_0011009'>Acute</z:hpo> Cerebral <z:hpo ids='HP_0001907'>Thromboembolism</z:hpo> (PROACT II) trial further demonstrated that patients with middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> can be treated up to 6 hours of <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001297'>stroke</z:hpo> with intra-arterial Pro-urokinase </plain></SENT>
<SENT sid="4" pm="."><plain>In spite of these results, community use of thrombolytic therapy remains dismally low </plain></SENT>
<SENT sid="5" pm="."><plain>Increasing <z:hpo ids='HP_0001297'>stroke</z:hpo> awareness in the community, establishing primary to tertiary <z:hpo ids='HP_0001297'>stroke</z:hpo> centers and physician education are possible methods of increasing utilization of thrombolytic therapy </plain></SENT>
</text></document>